Softwr

Research · head to head

Greenphire vs Remesh

Greenphire logo

Greenphire

Research

Clinical trial participant payments, reimbursement and travel, now part of Suvoda

From
On request
Rated
-
Full reviewWebsite
Remesh logo

Remesh

Research

Live AI-moderated conversations with hundreds of participants at once, analysed in real time

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Greenphire the standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.; Remesh pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • They diverge on capability: Greenphire covers ClinCard, Remesh covers Live moderated sessions.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Greenphire and Remesh actually diverge.

Attributes where Greenphire and Remesh differ
AttributeGreenphireRemesh
PlatformsWeb, iOS, AndroidWeb, API

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Greenphire

  • ClinCard
  • Direct to bank payment
  • Expense reimbursement
  • Travel and logistics
  • Site payments
  • Budgeting and benchmarking
  • Tax handling

Only in Remesh

  • Live moderated sessions
  • Collective dialogue
  • Flex asynchronous studies
  • Video research
  • Remy AI assistant
  • On-Demand Recruit
  • Real-time theme analysis
  • Practice sessions

What people use each for

The jobs each tool is most often brought in to do.

Greenphire

  • A global Phase III trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payablenot Remesh
  • A decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodationnot Remesh
  • A trial in a population where slow reimbursement drives dropout and same day payment materially helps retentionnot Remesh
  • A sponsor that wants site payment milestones and participant payments handled by one vendor rather than twonot Remesh

Remesh

  • A brand team that needs to test three positioning statements with 400 target customers and know by the end of the day which one lands and with whomnot Greenphire
  • An HR function running an employee listening session across several thousand staff where anonymity and volume both matternot Greenphire
  • A public affairs team needing rapid citizen consultation on a policy option with evidence of how widely each objection is heldnot Greenphire
  • An insights team that has to replace six focus groups with one session because fieldwork time has been cut and the decision cannot waitnot Greenphire

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Greenphire

  • The standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • Nothing is published on price, and the typical shape of a platform fee plus per participant and per transaction charges means the cost of a trial is not knowable until enrolment is known.
  • Payment method availability varies sharply by country, so a global protocol may end up with card payments in some regions and slow manual processes in others, which undermines the retention argument that justified the purchase.
  • Sites bear the administrative work of enrolling participants and triggering payments but are not the buyer, so adoption depends on the sponsor mandating it and site resistance is a real implementation risk.
  • Participant payments create tax reporting obligations that differ per jurisdiction, and the tooling helps but does not remove sponsor liability, so legal and finance review is required in every country the trial runs in.

Remesh

  • Pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • The public review picture is inconsistent in a way worth investigating: a small number of positive buyer reviews on G2 sit alongside a poor Trustpilot rating driven mostly by participant complaints, so ask directly how participants are recruited and compensated before running a study on your own customers.
  • Funding has slowed sharply, from a 25 million USD round in 2021 to a 4.25 million USD round in late 2022, so procurement teams at large organisations should expect to run a vendor viability review.
  • The collective dialogue mechanic rewards views that many participants recognise and vote for, which systematically under-weights genuinely novel minority insight, so it is a poor fit for exploratory discovery work where the outlier is the point.
  • The discussion guide builder, especially spreadsheet import, is reported as unreliable, and because sessions are live with recruited participants a tooling failure during setup is expensive rather than merely annoying.

Pricing, plan by plan

Greenphire

On request
  • Greenphire Patient Payments$undefined/year
    • Priced per study through a sales process
    • Typically a platform fee plus per participant and per transaction charges
    • Funding of the payment float is separate from the software fee

Remesh

On request
  • Remesh$undefined/year
    • Live moderated sessions
    • Flex asynchronous studies
    • Video research

Which should you pick?

Choose Greenphire if

  • You need clincard.
  • You work on Web, iOS, Android.
  • You also want direct to bank payment.
Greenphire review

Choose Remesh if

  • You need live moderated sessions.
  • You work on Web, API.
  • You also want collective dialogue.
Remesh review

Questions people ask

Is Greenphire or Remesh better?
Neither clearly leads. Greenphire starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Greenphire or Remesh?
Greenphire starts at On request and Remesh at On request.
Does Greenphire or Remesh run on more platforms?
Greenphire runs on Web, iOS, Android. Remesh runs on Web, API.
What is Greenphire best used for?
Greenphire is most often used for a global phase iii trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payable, a decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodation, a trial in a population where slow reimbursement drives dropout and same day payment materially helps retention, a sponsor that wants site payment milestones and participant payments handled by one vendor rather than two. Of those, a global phase iii trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payable and a decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodation are not what Remesh is typically brought in for.
What can Greenphire do that Remesh cannot?
Greenphire covers ClinCard, Direct to bank payment, Expense reimbursement, Travel and logistics. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.

Answered from the vendors’ own pages

Greenphire: Is Greenphire still sold?

Yes, as Greenphire Patient Payments on the Suvoda platform. The independent website and social presence have been consolidated into Suvoda.

Remesh: How many people can join one session?

Sessions are designed for several hundred participants at once, which is the core reason to choose it over a conventional focus group.

Greenphire: What is ClinCard?

The reloadable debit card Greenphire issues to participants. Greenphire Patient Payments was formerly known as ClinCard.

Remesh: Does it publish pricing?

No. Contracts are quoted annually, typically scoped by session volume, and third-party estimates place them in the tens of thousands of dollars per year.

Greenphire: Does it publish pricing?

No. Pricing is per study and quoted through sales, and funding the payments themselves is separate from the software fee.

Remesh: Can it replace a survey?

Not entirely. It produces open-ended language with agreement percentages, which is stronger than a survey for understanding reasoning but weaker for precise population estimates.

Greenphire: Can it pay participants outside the United States?

Yes, in more than thirty currencies, but the available payment method depends on the country.

Remesh: Does Remesh recruit participants for me?

Yes, through On-Demand Recruit, typically delivering a panel within about 24 hours, or you can bring your own list.

Share

Related pages

More on Greenphire

More on Remesh

Keep looking

Other head to heads